Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- PMID: 17998146
- DOI: 10.1016/j.jhep.2007.08.018
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
Abstract
Background/aims: The aim of the study was to determine the prognostic relevance of AKT and extracellular regulated kinases (ERK1/2), which are implied in the regulation of cell proliferation and apoptosis, in hepatocellular carcinoma (HCC).
Methods: This study comprised a series of 208 patients incorporating HCCs treated either by surgical resection (n = 109) or liver transplantation (n = 99). Immunohistochemically demonstrated phospho-ERK1/2 (pERK1/2) and phospho-AKT (pAKT) was correlated with a series of clinico-pathologically relevant parameters (EGFR, Cyclin-D1, HCV/HBV infection, liver cirrhosis, chronic alcohol abuse), proliferative activity, and apoptosis.
Results: Activation of ERK1/2 correlated statistically with the presence of HCV infection. pERK1/2 (P < 0.001) and pAKT (P = 0.052) expression showed a significant correlation with a decreased overall survival (OS). In multivariate Cox regression analysis pERK1/2 was identified as an independent prognostic parameter in HCC (P = 0.026).
Conclusions: Activation of ERK1/2 in HCC cancer indicates aggressive tumour behaviour and constitutes an independent prognostic factor. Furthermore our data confirm that HCV infection activates the ERK pathway and thereby might contribute to HCC carcinogenesis. Immunohistochemical determination of pERK1/2 status can thus be proposed as a promising candidate for the identification of high risk patients who may benefit from new anticancer drugs targeting the ERK-pathway.
Similar articles
-
Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.Liver Int. 2009 Mar;29(3):399-405. doi: 10.1111/j.1478-3231.2008.01798.x. Epub 2008 May 19. Liver Int. 2009. PMID: 18492014
-
Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis.J Clin Pathol. 2009 Aug;62(8):690-3. doi: 10.1136/jcp.2009.065888. J Clin Pathol. 2009. PMID: 19638539
-
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.Liver Int. 2011 Jul;31(6):810-6. doi: 10.1111/j.1478-3231.2011.02511.x. Epub 2011 Mar 29. Liver Int. 2011. PMID: 21645211
-
[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].Zentralbl Chir. 2009 Apr;134(2):127-35. doi: 10.1055/s-0028-1098881. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382043 Review. German.
-
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1269-77. doi: 10.1111/j.1365-2036.2008.03857.x. Epub 2008 Sep 20. Aliment Pharmacol Ther. 2008. PMID: 18808443 Review.
Cited by
-
Inhibition of HCV by the serpin antithrombin III.Virol J. 2012 Oct 2;9:226. doi: 10.1186/1743-422X-9-226. Virol J. 2012. PMID: 23031791 Free PMC article.
-
High interleukin-8 and/or extracellular signal-regulated kinase 2 expression predicts poor prognosis in patients with hepatocellular carcinoma.Oncol Lett. 2019 Nov;18(5):5215-5224. doi: 10.3892/ol.2019.10907. Epub 2019 Sep 23. Oncol Lett. 2019. PMID: 31612032 Free PMC article.
-
Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-ĸB Activation.In Vivo. 2018 Sep-Oct;32(5):1097-1103. doi: 10.21873/invivo.11351. In Vivo. 2018. PMID: 30150431 Free PMC article.
-
Crosstalk between beta-catenin and snail in the induction of epithelial to mesenchymal transition in hepatocarcinoma: role of the ERK1/2 pathway.Int J Mol Sci. 2013 Oct 16;14(10):20768-92. doi: 10.3390/ijms141020768. Int J Mol Sci. 2013. PMID: 24135872 Free PMC article.
-
Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria.Cell Death Dis. 2014 Feb 20;5(2):e1078. doi: 10.1038/cddis.2014.51. Cell Death Dis. 2014. PMID: 24556693 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous